Insights from comprehensive multiple receptor docking to HDAC8

Journal of Molecular Modeling

Volumn 18, Issue 8, 2012, Pages 3927-3939

  Brunsteiner, Michael ^a,b   Petukhov, Pavel A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b GRAZ UNIVERSITY OF TECHNOLOGY   (Austria)

Author keywords

Binding site flexibility; Docking; Histone deacetylase 8; Multiple receptor

Indexed keywords

HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; ISOXAZOLE DERIVATIVE; METAL ION; PYRAZOLE DERIVATIVE;

ARTICLE; BINDING SITE; CROSS LINKING; CRYSTAL STRUCTURE; DRUG POTENCY; ENZYME BINDING; HYDROGEN BOND; IC 50; LIGAND BINDING; MOLECULAR DOCKING; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN INTERACTION; PROTEIN STRUCTURE;

CATALYTIC DOMAIN; COMPUTER SIMULATION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; ISOXAZOLES; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PYRAZOLES; REPRESSOR PROTEINS; STRUCTURAL HOMOLOGY, PROTEIN;

EID: 84864695108     PISSN: 16102940     EISSN: 09485023     Source Type: Journal    
DOI: 10.1007/s00894-011-1297-8     Document Type: Article

References (58)

1. Rundlett SE, Carmen AA, Kobayashi R, Bavykin S, Turner BM, Grunstein M (1996) HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription. Proc Natl Acad Sci USA 93:14503-14508 (Pubitemid 26418996)
2. Kouzarides T (2000) Acetylation: a regulatory modification to rival phosphorylation? EMBO J 19:1176-1179. doi:10.1093/emboj/19.6.1176 (Pubitemid 30151013)
3. Villar-Garea A, Esteller M (2004) Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer 112:171-178. doi:10.1002/ijc.20372 (Pubitemid 39244355)
4. Balasubramanian S, Verner E, Buggy JJ (2009) Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett 280:211-221. doi:10.1016/j.canlet.2009.02.013
5. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M (2008) Determination of the class and isoform selectivity of smallmolecule histone deacetylase inhibitors. Biochem J 409:581-589. doi:10.1042/BJ20070779 (Pubitemid 351184977)
6. Chen YD, Jiang YJ, Zhou JW, Yu QS, You QD (2008) Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling. J Mol Graph Model 26:1160-1168. doi:10.1016/j.jmgm.2007.10.007 (Pubitemid 351374853)
7. Guo Y, Xiao J, Guo Z, Chu F, Cheng Y, Wu S (2005) Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses. Bioorg Med Chem 13:5424-5434. doi:10.1016/j.bmc.2005.05. 016 (Pubitemid 41132620)
8. Ragno R, Simeoni S, Rotili D, Caroli A, Botta G, Brosch G, Massa S, Mai A (2008) Class II-selective histone deacetylase inhibitors. Part 2: alignment-independent GRIND 3-D QSAR, homology and docking studies. Eur J Med Chem 43:621-632. doi:10.1016/j.ejmech.2007.05.004 (Pubitemid 351323996)
9. Ragno R, Simeoni S, Valente S, Massa S, Mai A (2006) 3-D QSAR studies on histone deacetylase inhibitors. A GOLPE/GRID approach on different series of compounds. J Chem Info Model 46:1420-1430. doi:10.1021/ci050556b (Pubitemid 43999186)
10. Zhu Y, Li HF, Lu S, Zheng YX, Wu Z, Tang WF, Zhou X, Lu T (2010) Investigation on the isoform selectivity of histone deacetylase inhibitors using chemical feature based pharmacophore and docking approaches. Eur J Med Chem 45:1777-1791. doi:10.1016/j.ejmech.2010.01.010
11. Tang H, Wang XS, Huang XP, Roth BL, Butler KV, Kozikowski AP, Jung M, Tropsha A (2009) Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation. J Chem Info Model 49:461-476. doi:10.1021/ci800366f
12. Di Micco S, Terracciano S, Bruno I, Rodriquez M, Riccio R, Taddei M, Bifulco G (2008) Molecular modeling studies toward the structural optimization of new cyclopeptide-based HDAC inhibitors modeled on the natural product FR235222. Bioorg Med Chem 16:8635-8642. doi:10.1016/j.bmc.2008.08.003
13. Grolla AA, Podesta V, Chini MG, Di Micco S, Vallario A, Genazzani AA, Canonico PL, Bifulco G, Tron GC, Sorba G, Pirali T (2009) Synthesis, biological evaluation, and molecular docking of Ugi products containing a zinc-chelating moiety as novel inhibitors of histone deacetylases. J Med Chem 52:2776-2785. doi:10.1021/jm801529c
14. Huang WJ, Chen CC, Chao SW, Lee SS, Hsu FL, Lu YL, Hung MF, Chang CI (2010) Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase. Chem Med Chem 5:598-607. doi:10.1002/cmdc.200900494
15. Lu Q, Wang DS, Chen CS, Hu YD (2005) Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem 48:5530-5535. doi:10.1021/jm0503749 (Pubitemid 41209250)
16. Mai A, Valente S, Nebbioso A, Simeoni S, Ragno R, Massa S, Brosch G, De Bellis F, Manzo F, Altucci L (2009) New pyrrolebased histone deacetylase inhibitors: binding mode, enzyme-and cell-based investigations. Int J Biochem Cell Biol 41:235-247. doi:10.1016/j.biocel.2008.09.002
17. Pirali T, Faccio V, Mossetti R, Grolla AA, Di Micco S, Bifulco G, Genazzani AA, Tron GC (2010) Synthesis, molecular docking and biological evaluation as HDAC inhibitors of cyclopeptide mimetics by a tandem three-component reaction and intramolecular [3 +2] cycloaddition. Mol Divers 14:109-121. doi:10.1007/s11030-009-9153-9
18. Wang DF, Wiest O, Helquist P, Lan-Hargest HY, Wiech NL (2004) On the function of the 14 A long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors. J Med Chem 47:3409-3417. doi:10.1021/jm0498497 (Pubitemid 38746091)
19. Ortore G, Di CF, Martinelli A (2009) Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization of activity trends and selectivities. J Chem Info Model 49:2774-2785. doi:10.1021/ci900288e
20. Wang DF, Helquist P, Wiech NL, Wiest O (2005) Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. J Med Chem 48:6936-6947. doi:10.1021/jm0505011 (Pubitemid 41533115)
21. Estiu G, West N, Mazitschek R, Greenberg E, Bradner JE, Wiest O (2010) On the inhibition of histone deacetylase 8. Bioorg Med Chem 18:4103-4110. doi:10.1016/j.bmc.2010.03.080
22. Raha K, Merz KM Jr (2004) A quantum mechanics-based scoring function: study of zinc ion-mediated ligand binding. J Am Chem Soc 126:1020-1021. doi:10.1021/ja038496i (Pubitemid 38140722)
23. Irwin JJ, Raushel FM, Shoichet BK (2005) Virtual screening against metalloenzymes for inhibitors and substrates. Biochemistry 44:12316-12328. doi:10.1021/bi050801k (Pubitemid 41324325)
24. Park H, Lee S (2004) Homology modeling, force field design, and free energy simulation studies to optimize the activities of histone deacetylase inhibitors. J Comput Aided Mol Des 18:375-388. doi:10.1007/s10822-004-2283-3 (Pubitemid 40069136)
25. Ryde U (1995) Molecular dynamics simulations of alcohol dehydrogenase with a four-or five-coordinate catalytic zinc ion. Proteins 21(1):40-56. doi:10.1002/prot.340210106
26. Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ, Luong C, Arvai A, Buggy JJ, Chi E, Tang J, Sang BC, Verner E, Wynands R, Leahy EM, Dougan DR, Snell G, Navre M, Knuth MW, Swanson RV, McRee DE, Tari LW (2004) Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 12:1325-1334. doi:10.1016/j.str.2004.04.012 (Pubitemid 38900774)
27. Sherman W, Day T, Jacobson MP, Friesner RA, Farid R (2006) Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 49:534-553. doi:10.1021/Jm050540c (Pubitemid 43157487)
28. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD (2003) Improved protein-ligand docking using GOLD. Proteins Struct Funct Gen 52:609-623. doi:10.1002/Prot.10465 (Pubitemid 37034158)
29. Dowling DP, Gantt SL, Gattis SG, Fierke CA, Christianson DW (2008) Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors. Biochemistry 47:13554-13563. doi:10.1021/bi801610c
30. Vannini A, Volpari C, Filocamo G, Casavola EC, Brunetti M, Renzoni D, Chakravarty P, Paolini C, De Francesco R, Gallinari P, Steinkuhler C, Di Marco S (2004) Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 101:15064-15069. doi:10.1073/pnas.0404603101 (Pubitemid 39391719)
31. Vannini A, Volpari C, Gallinari P, Jones P, Mattu M, Carfi A, De Francesco R, Steinkuhler C, Di Marco S (2007) Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex. EMBO Rep 8:879-884. doi:10.1038/sj.embor.7401047 (Pubitemid 350001433)
32. He B, Velaparthi S, Pieffet G, Pennington C, Mahesh A, Holzle DL, Brunsteiner M, van Breemen R, Blond SY, Petukhov PA (2009) Binding ensemble profiling with photoaffinity labeling (BEProFL) approach: mapping the binding poses of HDAC8 inhibitors. J Med Chem 52:7003-7013. doi:10.1021/jm9005077
33. Neelarapu R, Holzle DL, Velaparthi S, Bai H, Brunsteiner M, Blond SY, Petukhov PA (2011) Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole-and pyrazole-based histone deacetylase probes. J Med Chem 54:4350-4364. doi:10.1021/jm2001025
34. Bora-Tatar G, Dayangac-Erden D, Demir AS, Dalkara S, Yelekci K, Erdem-Yurter H (2009) Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: activity and docking studies. Bioorg Med Chem 17:5219-5228. doi:10.1016/j.bmc.2009.05.042
35. Kirchmair J, Markt P, Distinto S, Schuster D, Spitzer GM, Liedl KR, Langer T, Wolber G (2008) The protein data bank (PDB), its related services and software tools as key components for in silico guided drug discovery. J Med Chem 51:7021-7040. doi:10.1021/Jm8005977
36. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 25:1605-1612. doi:10.1002/jcc.20084
37. Eswar N, Webb B, Marti-Renom MA, Madhusudhan MS, Eramian D, Shen MY, Pieper U, Sali A (2007) Comparative protein structure modeling using MODELLER. Curr Protoc Prot Sci 2:2.9. doi:10.1002/0471140864.ps0209s50
38. Word JM, Lovell SC, Richardson JS, Richardson DC (1999) Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation. J Mol Biol 285:1735-1747 (Pubitemid 29060467)
39. Chemical Computing Group Inc. (2010) Molecular Operating Environment (MOE). Chemical Computing Group Inc., Montreal. http://www.chemcomp. com. 2010
40. Vanommeslaeghe K, Loverix S, Geerlings P, Tourwe D (2005) DFT-based ranking of zinc-binding groups in histone deacetylase inhibitors. Biorg Med Chem 13:6070-6082. doi:10.1016/j.bmc.2005.06.009 (Pubitemid 41399918)
41. Jones G, Willett P, Glen RC (1995) Molecular recognition of receptor-sites using a genetic algorithm with a description of desolvation. J Mol Biol 245:43-53. doi:10.1016/S0022-2836 (95) 80037-9
42. Jain AN (2007) Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J Comput Aided Mol Des 21:281-306. doi:10.1007/s10822-007-9114-2 (Pubitemid 46630055)
43. Mayo SL, Olafson BD, Goddard WA (1990) Dreiding-a generic force-field for molecular simulations. J Phys Chem 94:8897-8909. doi:10.1021/j100389a010
44. Pieffet G, Petukhov PA (2009) Parameterization of aromatic azido groups: application as photoaffinity probes in molecular dynamics studies. J Mol Model 15:1291-1297. doi:10.1007/s00894-009-0488-z
45. Jakalian A, Jack DB, Bayly CI (2002) Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. J Comput Chem 23:1623-1641. doi:10.1002/Jcc.10128 (Pubitemid 35330860)
46. Openeye Scientific Software (2010) molcharge. Openeye Scientific Software, Santa Fe
47. Guha R, Howard MT, Hutchison GR, Murray-Rust P, Rzepa H, Steinbeck C, Wegner J, Willighagen EL (2006) The Blue Obelisk-interoperability in chemical informatics. J Chem Info Model 46:991-998. doi:10.1021/ci050400b (Pubitemid 43999142)
48. R Foundation for Statistical Computing (2009) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
49. Huang N, Shoichet BK (2008) Exploiting ordered waters in molecular docking. J Med Chem 51:4862-4865. doi:10.1021/jm8006239
50. Barril X, Fradera X (2006) Incorporating protein flexibility into docking and structure-based drug design. Expert Opin Drug Discov 1:1-14
51. Rueda M, Bottegoni G, Abagyan R (2010) Recipes for the selection of experimental protein conformations for virtual screening. J Chem Info Model 50:186-193. doi:10.1021/ci9003943
52. Yoon S, Welsh WJ (2004) Identification of a minimal subset of receptor conformations for improved multiple conformation docking and two-step scoring. J Chem Inf Comput Sci 44:88-96. doi:10.1021/ci0341619
53. Zhong H, Tran LM, Stang JL (2009) Induced-fit docking studies of the active and inactive states of protein tyrosine kinases. J Mol Graph Model 28:336-346. doi:10.1016/j.jmgm.2009.08.012
54. Barril X, Morley SD (2005) Unveiling the full potential of flexible receptor docking using multiple crystallographic structures. J Med Chem 48:4432-4443. doi:10.1021/Jm048972v (Pubitemid 40884945)
55. Wu R, Lu Z, Cao Z, Zhang Y (2011) Zinc chelation with hydroxamate in histone deacetylases modulated by water access to the linker binding channel. J Am Chem Soc 133:6110-6113. doi:10.1021/ja111104p
56. Wang D, Helquist P, Wiest O (2007) Zinc binding in HDAC inhibitors: a DFT study. J Org Chem 72:5446-5449. doi:10.1021/jo070739s (Pubitemid 47056245)
57. Gantt SL, Gattis SG, Fierke CA (2006) Catalytic activity and inhibition of human histone deacetylase 8 is dependent on the identity of the active site metal ion. Biochemistry 45:6170-6178. doi:10.1021/bi060212u (Pubitemid 43727109)
58. Chen Y, Lopez-Sanchez M, Savoy DN, Billadeau DD, Dow GS, Kozikowski AP (2008) A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum. J Med Chem 51:3437-3448. doi:10.1021/jm701606b (Pubitemid 351875000)